Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

AI-guided personalized T cell receptor transgenic T cell therapy against cancer

Objectif

"Personalised T cell therapy has shown remarkable success in cancer therapy, however the antigens that T cells recognize to kill tumor cells are dependent on the individual tumor, T cell receptor (TCR) profile and antigen presentation machinery. AI-TreatCancer will leverage predicTCR, a proprietary AI-guided classifier that identifies tumor-killing TCRs from patient samples, decreasing the time to identify therapeutic TCRs from 3-4 months to under 2 weeks.
In the ERC Advanced Grant (ERC-2023-ADG #101141901 — Characterizing and harnessing tumor-reactive T cells in the brain; “CENTRIC-BRAIN”), predicTCR was extensively validated, including resolving the target antigens of many TCRs. Following discussions with the regulator we identified key regulatory compliance obstacles that must be resolved prior to implementing predicTCR in a first-in-human, AI-guided personalised transgenic T cell therapy trial - the first step to securing investment for market entry.
Firstly we will develop robust quality control metrics that automatically identify compromised patient samples before analysis, preventing false-positive TCR identification that could lead to ineffective therapies. Secondly AI-TreatCancer will establish regulatory compliance for the use of predicTCR in selecting tumor-targeting TCRs for a clinical trial.
The project's high-gain potential extends beyond immediate clinical application. Success would establish a new regulatory framework for AI-assisted companion diagnostics in cell therapies, creating a template for future innovations. A compliant predicTCR would enable systematic TCR discovery, including in rare cancers currently excluded from therapeutic development, and potentially identify cross-entity shared tumor-reactive TCRs for “off-the-shelf” cell therapies. Furthermore, the comprehensive quality control pipeline would set industry standards for single-cell sequencing in clinical applications, benefiting the broader precision medicine field.


"

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2025-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Contribution nette de l'UE
€ 150 000,00
Adresse
IM NEUENHEIMER FELD 280
69120 Heidelberg
Allemagne
Région
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Bénéficiaires (1)